<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022824</url>
  </required_header>
  <id_info>
    <org_study_id>2017034</org_study_id>
    <nct_id>NCT04022824</nct_id>
  </id_info>
  <brief_title>Vascular Responses After Percutaneous Coronary Intervention With Stenting In Patients With Obstructive Sleep Apnea</brief_title>
  <acronym>VISION</acronym>
  <official_title>Vascular Responses After Percutaneous Coronary Intervention With Stenting In Patients With Obstructive Sleep ApNea: A Serial 3-Vessel Optical Coherence Tomography Study (VISION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is an increasingly common chronic disorder in adults. Compared
      to the general population, OSA occurs more often in patients with coronary artery disease
      (CAD), with a reported prevalence of 38% to 65%. Emerging evidence indicates OSA initiates
      and exacerbates coronary atherosclerosis. Moreover, several observational studies indicate
      the presence of OSA was associated with higher rate of restenosis and repeat
      revascularization (mainly attributed non-culprit lesion revascularization) after percutaneous
      coronary intervention (PCI). OSA might initiate endothelial injury by repetitive bursts of
      sympathetic activity that occur with apneas and hypopneas. Moreover, untreated OSA reduces
      endothelial repair capacity. Whether OSA could exacerbate neointimal proliferation and plaque
      progression in the non-culprit lesion after drug-eluting stent (DES) implantation remains
      less studied. The investigators aimed to evaluate neointimal proliferation and strut coverage
      within stent segment as well as changes of plaque volume and morphology in the non-culprit
      lesion by optical coherence tomography (OCT) in patients with versus without OSA at 12-month
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative proliferation volume within stent segment (% of stent volume)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total lipid volume index in the non-culprit lesion</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum area stenosis within stent segment</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as minimal lumen area divided by the mean of reference lumen area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total proliferation volume within stent segment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum proliferation area within stent segment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal lumen area within stent segment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of uncovered struts, uncovered and apposed struts, malapposed struts</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of neoatherosclerosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lipid volume index</measure>
    <time_frame>Baseline</time_frame>
    <description>Defined as the averaged lipid angle multiplied by lipid length; including culprit and non-culprit lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of TCFA</measure>
    <time_frame>Baseline</time_frame>
    <description>In the culprit and non-culprit lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of plaque rupture</measure>
    <time_frame>Baseline</time_frame>
    <description>In the culprit and non-culprit lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major adverse cardiac events (cardiac death, myocardial infarction, or ischemic-driven repeat revascularization)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum lipid angle</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Calcium volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Macrophage volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of total lipid volume index with AHI</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of total lipid volume index with lowest SpO2</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of total lipid volume index total time with SpO2 &lt;90%</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total lipid volume index stratified by sex in both groups</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total lipid volume index stratified by obesity in both groups</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total lipid volume index stratified by diabetes in both groups</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of individual cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Including all-cause death, cardiac death, myocardial infarction, target vessel revascularization, target lesion revascularization, non-target vessel revascularization, hospitalization for unstable angina</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Obstructive Sleep Apnea of Adult</condition>
  <arm_group>
    <arm_group_label>OSA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-OSA</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OSA</intervention_name>
    <description>Patients with OSA (apnea hypopnea index ≥15) based on sleep study</description>
    <arm_group_label>OSA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-OSA</intervention_name>
    <description>Patients without OSA (apnea hypopnea index ＜15) based on sleep study</description>
    <arm_group_label>Non-OSA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing PCI with stenting and 3-vessel OCT and receiving overnight sleep study
        (polygraphy)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 80 years old

          2. Patients undergoing PCI with stenting in at least one de novo lesion in a native
             coronary artery

          3. 3-vessel OCT was available visually (at least one pullback/vessel)

          4. Written informed consent

        Exclusion Criteria:

          1. Predominantly central sleep apnea (CSA, ≥50% central events or central apnea hypopnea
             index ≥10/h)

          2. Previous or current use of continuous positive airway pressure (CPAP)

          3. Cardiogenic shock (systolic arterial pressure &lt;90mmHg), congestive heart failure (NYHA
             or Killip≥3)

          4. STEMI within 1 week

          5. Prior PCI or CABG

          6. Chronic kidney disease [eGFR&lt;60ml/(min*1.73m2)]

          7. Aortic-coronary ostial lesion

          8. Left main lesion

          9. Chronic total occlusion

         10. In-stent restenotic lesion

         11. A tortuous vessel and/or severely calcified lesion or severe stenosis and the OCT
             catheter could not pass across the lesion

         12. Massive residual thrombus on angiography despite thrombus aspiration or thrombectomy

         13. Planned elective PCI within 12 months

         14. Severe comorbidities: eg. malignancy (life expectancy &lt;2 years)

         15. Known or planned pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shao-Ping Nie, MD, PhD</last_name>
    <phone>86-10-84005256</phone>
    <email>spnie@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Wang, MD</last_name>
    <phone>86-10-84005255</phone>
    <email>spaceeye123@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 14, 2019</last_update_submitted>
  <last_update_submitted_qc>July 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Emergency &amp; Critical Care Center</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Obstructive sleep apnea</keyword>
  <keyword>Optical coherence tomography</keyword>
  <keyword>Vascular response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

